Refine
Keywords
- Cell Membrane (4)
- Glucocorticoid (3)
- Cells (2)
- Spectroscopy (2)
- Cell (1)
- Membrane (1)
- Regenerative Medicine (1)
- Shockwave Therapy (1)
- Steroid Receptors (1)
- Tissue Regeneration (1)
Department
Flourescence Correlation Spectroscopy (FCS): A New Tool for Studying Membrane Steroid Receptors
(2003)
Investigation of Putative Membrane Glucocorticoid Binding Sites on Single Living Cells by FCS
(2003)
BACKGROUND:
Cell-based therapies with autologous adipose tissue-derived cells have shown great potential in several clinical studies in the last decades. The majority of these studies have been using the stromal vascular fraction (SVF), a heterogeneous mixture of fibroblasts, lymphocytes, monocytes/macrophages, endothelial cells, endothelial progenitor cells, pericytes and adipose-derived stromal/stem cells (ASC) among others. Although possible clinical applications of autologous adipose tissue-derived cells are manifold, they are limited by insufficient uniformity in cell identity and regenerative potency.
METHODS:
In our experimental set-up, low-energy extracorporeal shock wave therapy (ESWT) was performed on freshly obtained human adipose tissue and isolated adipose tissue SVF cells aiming to equalize and enhance stem cell properties and functionality.
RESULTS:
After ESWT on adipose tissue we could achieve higher cellular adenosine triphosphate (ATP) levels compared with ESWT on the isolated SVF as well as the control. ESWT on adipose tissue resulted in a significantly higher expression of single mesenchymal and vascular marker compared with untreated control. Analysis of SVF protein secretome revealed a significant enhancement in insulin-like growth factor (IGF)-1 and placental growth factor (PLGF) after ESWT on adipose tissue.
DISCUSSION:
Summarizing we could show that ESWT on adipose tissue enhanced the cellular ATP content and modified the expression of single mesenchymal and vascular marker, and thus potentially provides a more regenerative cell population. Because the effectiveness of autologous cell therapy is dependent on the therapeutic potency of the patient's cells, this technology might raise the number of patients eligible for autologous cell transplantation.